Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3 Meeting Abstract
| Authors: | Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K. K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N. S.; Costa, L.; Vij, R.; Bahlis, N. J.; Moreau, P.; Solomon, S. R.; Abrahamsen, I. W.; Baz, R.; Broijl, A.; Chen, C.; Jagannath, S.; Raje, N. S.; Scheid, C.; Delforge, M.; Benjamin, R.; Pabst, T.; Iida, S.; Berdeja, J. G.; Truppel-Hartmann, A.; Bhatnagar, R.; Wu, F.; Piasecki, J.; Eliason, L.; Dhanda, D.; Felten, J.; Caia, A.; Cook, M.; Popa-McKiver, M.; Giralt, S. A. |
| Abstract Title: | Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3 |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 1028 |
| Language: | English |
| ACCESSION: | WOS:001159306704052 |
| DOI: | 10.1182/blood-2023-178933 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
